Radient Pharmaceuticals Corporation fka RXPC

[livinginsv]

CMS decides the pricing of screening tests . . .

if and when either company submits a full PMA to the FDA and gets approval, then CMS will review and price the tests . . . the problem with GCDx's test is it is a LDT, and CMS will not review it . . . provista doesn't have a LC test in their pipeline yet, so they have years to go . . . so does EXAS, but with the EXAS CC test raking in millions per month, they have the cash flow to develop and submit a PMA . . .

no one will pay 99.- for a LDT . . . ask WG . . . the govt and the HC companies will pay whatever CMS recommends, NO OUT OF POCKET COSTS to the patient . . . this is key . . .